In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...

FARE's indicator report tracks the growing public health challenge of food allergy in the United States—a top-tier public health issue—highlighting key data that can guide future research efforts.

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.

How far can Robert Kennedy junior push state policies? West Virginia will provide an answer ...

Dupilumab was safe and effective for the treatment of patients with severe AD who were aged 6 months to 5 years in a real-world study.

New FDA approval for Wakix (pitolisant) allows for the treatment of cataplexy in pediatric narcolepsy patients.

The FDA has taken down a webpage warning about therapies and products making “false claims” of treating autism. It’s part of a series of actions the agency has taken under Secretary Robert F. Kennedy ...

The pooling blood indicated that the baby had a severe vitamin K deficiency - something usually prevented by a shot at birth.

Last week, during a stop in Nashville on his Take Back Your Health tour, the Health and Human Services secretary brought up the technology between condemning ultra-processed foods and urging Americans ...

Regenxbio advances RGX-314 and RGX-202 pipelines for AMD and Duchenne while navigating recent FDA program setbacks. Read why RGNX stock is downgraded to buy.

Medication isn’t the enemy. But when we pause to understand why a child is struggling, we often find more effective paths to healing. Children deserve care that looks deeper.